Manganese-tannic acid immunomodulators potentiate PDGFRβ CAR-T cell function for additive therapy against liver fibrosis - PubMed
3 hours ago
- #Liver fibrosis
- #Nanoparticle immunomodulator
- #CAR-T therapy
- Manganese-tannic acid (MT) nanoparticles are designed as immunomodulators to enhance PDGFRβ CAR-T cell function for treating liver fibrosis.
- PDGFRβ CAR-T cells specifically target activated hepatic stellate cells (aHSCs), a key driver in liver fibrosis, with PDGFRβ upregulated during activation.
- MT nanoparticles anchor to PDGFRβ CAR-T cells, remodel the hepatic fibrotic microenvironment, and improve anti-fibrotic outcomes through additive therapy.
- Mechanistically, MT nanoparticles boost proliferation and cytotoxicity of PDGFRβ CAR-T cells by upregulating the RAS signaling pathway activity.
- The combined strategy shows excellent anti-fibrotic effects, offering a promising therapeutic regimen for hepatic fibrosis.